Barely Significant
← all phrases

“a numerical trend”

1,013 sentences · 1,013 papers · 1,817 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

There was a numerical trend suggesting a possible shift in breathing route from oronasal to nasal during both phases of the study (Table 3 ); however, statistical analysis of the data from the active phase by both Wilcoxon test ( P = 0.359) and two-sample t test ( P = 0.559) showed that this trend did not reach statistical significance.
Nevertheless, there was a numerical trend for improved results in the modified bicaval group regarding postoperative epinephrine therapy (98 ± 44 h), norepinephrine therapy (76 ± 72 h), va-ECMO/microaxial pumps (10.0%) and successful weaning rate from va-ECMO/microaxial pump (100.0%) compared to biatrial (120 ± 92 h; 235 ± 351 h; 27.0% respectively 90.0%) and bicaval technique (153 ± 153 h; 166 ± 188 h; 28.8% respectively 70.9%).
Interestingly, in another study, there was a numerical trend towards a higher 30-day mortality among patients who underwent redo-TAVR for procedural versus THV failure, but this was not statistically significant (5.4% versus 1.4%, respectively; p=0.427).[ 8 ] Periprocedural complications were low, and the 30-day survival was 94.6% in those undergoing redo-TAVR for procedural failure and 98.5% in those with THV failure (p=0.101).
The study was not powered to demonstrate an EFS benefit, but an exploratory analysis at 5-year follow up showed a numerical trend in favor of the docetaxel/trastuzumab/pertuzumab arm compared with docetaxel/trastuzumab (84% versus 81%; HR 0.69; 95% CI 0.34–1.40). 40 TRYPHAENA was a three-arm study enrolling 225 patients with HER2+ tumors 2 cm or larger. 39 It primarily aimed to evaluate the cardiac safety of three pertuzumab and trastuzumab-containing regimens.
tion or no clearly documented rationale; (iii) among patients with non-bleeding-related de-escalation, the rationale for switching to clopidogrel was often reasons that could have been addressed with the use of prasugrel to avoid the switch and prevent exposure to ischemic risks; and (iv) there was a numerical trend for increased myocardial infarction among patients with non-bleeding-related de-escalation.